NCT00024414 is a Phase 2 clinical trial of DHA-paclitaxel in Prostate Cancer, sponsored by Theradex.

Who is sponsoring NCT00024414?

NCT00024414 is sponsored by Theradex.

What drugs are being tested in NCT00024414?

Interventions in NCT00024414: DHA-paclitaxel.

What condition does NCT00024414 study?

NCT00024414 studies Prostate Cancer.

Is NCT00024414 still recruiting?

NCT00024414 is currently status unknown. Last updated 23 July 2008.

Last reviewed 2008-07-23 · How we verify

NCT00024414

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Hormone-Refractory Prostate Cancer

Status unknown Phase 2 Last updated 23 July 2008

What this trial tests

Phase 2 trial testing DHA-paclitaxel in Prostate Cancer. Status unknown.

Timeline

1 April 2001

Quick facts

Lead sponsor	Theradex
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Primary purpose	treatment
Start date	1 April 2001
Sites	8 locations across United States

Drugs / interventions tested

DHA-paclitaxel — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Theradex — full company profile →

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting Autophagy with Natural Products as a Potential Therapeutic Approach for Cancer.
Al-Bari MAA, Ito Y, Ahmed S, Radwan N, et al · · 2021 · cited 34× · PMID 34575981 · DOI 10.3390/ijms22189807

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00024414 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Theradex
Last refreshed: 23 July 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00024414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing